The future is bright for gene therapy. Last year, the Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for pioneering CRISPR, a type of gene editing. By using genes as medicine, the industry can address the underlying cause of a disease at the cellular level, and results could potentially be achieved in just one treatment. As the industry emphasizes its commitment to rare disease patients, gene therapy is an attainable opportunity to improve the lives of patients who have complex diseases with significant unmet needs. We’re happy to share with you original, actionable editorial that illustrates the sector’s commitment to advancements in gene therapy.